Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic cholestatic liver diseases. However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose ...

Report with the AI impact on market trends- The global ursodeoxycholic acid market size is estimated to grow by USD ...

In patients with chronic liver disease, including PBC, ursodeoxycholic acid shows promise as an adjunctive therapy for COVID-19 infection.

The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) ...

荧光素标记透明质酸 FITC-HA CY5标记透明质酸 CY5-HA18k 吲哚菁绿标记透明质酸 ICG-HA 荧光素标记甲基丙烯酰化透明质酸 FITC-HAMA CY3标记甲基丙烯酰化透明质酸 CY3-HAMA 荧光素标记海藻酸钠 FITC-Sodium alginate CY5标记海藻酸钠 CY5-Sodium alginate CY5-熊去氧胆酸 CY5-Ursodeoxycholic ...

Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH. Methods: Western and Chinese databases were ...

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes includes anticholestatic therapy with ursodeoxycholic acid and immunosuppressive therapy with corticosteroids and azathioprine.

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

Discover all the brand names or Trade names of generic drug called Ursodeoxycholic Acid. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking ...